195 related articles for article (PubMed ID: 29191574)
21. Collapsing glomerulopathy: a clinically and pathologically distinct variant of focal segmental glomerulosclerosis.
Detwiler RK; Falk RJ; Hogan SL; Jennette JC
Kidney Int; 1994 May; 45(5):1416-24. PubMed ID: 8072254
[TBL] [Abstract][Full Text] [Related]
22. [Valganciclovir maintenance therapy in AIDS: treatment failure due to the development of cytomegalovirus resistance to ganciclovir].
Couzigou C; Mazeron MC; Escaut L; Merad M; Vittecoq D
Med Mal Infect; 2005 Feb; 35(2):98-100. PubMed ID: 15780901
[No Abstract] [Full Text] [Related]
23. Treatment with IFN-{alpha}, -{beta}, or -{gamma} is associated with collapsing focal segmental glomerulosclerosis.
Markowitz GS; Nasr SH; Stokes MB; D'Agati VD
Clin J Am Soc Nephrol; 2010 Apr; 5(4):607-15. PubMed ID: 20203164
[TBL] [Abstract][Full Text] [Related]
24. Repopulation of ganciclovir-resistant cytomegalovirus by wild-type virus.
Drew WL; Liu C
Clin Transplant; 2012; 26(6):949-52. PubMed ID: 22774759
[TBL] [Abstract][Full Text] [Related]
25. Focal segmental glomerulosclerosis in nephrotic adults: presentation, prognosis, and response to therapy of the histologic variants.
Chun MJ; Korbet SM; Schwartz MM; Lewis EJ
J Am Soc Nephrol; 2004 Aug; 15(8):2169-77. PubMed ID: 15284302
[TBL] [Abstract][Full Text] [Related]
26. Collapsing Focal Segmental Glomerulosclerosis in Viral Infections.
Muehlig AK; Gies S; Huber TB; Braun F
Front Immunol; 2021; 12():800074. PubMed ID: 35095882
[TBL] [Abstract][Full Text] [Related]
27. Initial experience with oral valganciclovir for pre-emptive cytomegalovirus therapy after lung transplantation.
Aigner C; Jaksch P; Winkler G; Czebe K; Taghavi S; Marta G; Klepetko W
Wien Klin Wochenschr; 2005 Jul; 117(13-14):480-4. PubMed ID: 16091875
[TBL] [Abstract][Full Text] [Related]
28. Successful treatment with oral valganciclovir in immunocompetent infant with gastrointestinal manifestations of cytomegalovirus infection.
Buonuomo PS; Maurizi P; Valentini P; Mastrangelo S; Lazzareschi I; Ridola V; Riccardi R
J Perinatol; 2006 Oct; 26(10):648-9. PubMed ID: 17006527
[TBL] [Abstract][Full Text] [Related]
29. Remission of IgA nephropathy following treatment of cytomegalovirus infection with ganciclovir.
Ortmanns A; Ittel TH; Schnitzler N; Handt S; Helmchen U; Sieberth G
Clin Nephrol; 1998 Jun; 49(6):379-84. PubMed ID: 9696435
[TBL] [Abstract][Full Text] [Related]
30. Oral Valganciclovir as a Preemptive Treatment for Cytomegalovirus (CMV) Infection in CMV-Seropositive Liver Transplant Recipients.
Kim JM; Kwon CH; Joh JW; Ha YE; Sinn DH; Choi GS; Peck KR; Lee SK
PLoS One; 2015; 10(5):e0123554. PubMed ID: 25942443
[TBL] [Abstract][Full Text] [Related]
31. A prospective assessment of valganciclovir for the treatment of cytomegalovirus infection and disease in transplant recipients.
Humar A; Siegal D; Moussa G; Kumar D
J Infect Dis; 2005 Oct; 192(7):1154-7. PubMed ID: 16136456
[TBL] [Abstract][Full Text] [Related]
32. Human cytomegalovirus and kidney transplantation: a clinician's update.
De Keyzer K; Van Laecke S; Peeters P; Vanholder R
Am J Kidney Dis; 2011 Jul; 58(1):118-26. PubMed ID: 21684438
[TBL] [Abstract][Full Text] [Related]
33. Nephrotic syndrome with acute kidney injury due to focal segmental glomerulosclerosis following long-term treatment with minodronate.
Morinishi T; Nawata A; Konishi R; Ono E; Takaori K; Maeda S
CEN Case Rep; 2022 Feb; 11(1):120-125. PubMed ID: 34455572
[TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetics of valganciclovir and ganciclovir in renal impairment.
Czock D; Scholle C; Rasche FM; Schaarschmidt D; Keller F
Clin Pharmacol Ther; 2002 Aug; 72(2):142-50. PubMed ID: 12189361
[TBL] [Abstract][Full Text] [Related]
35. Valganciclovir for the prevention of complications of late cytomegalovirus infection after allogeneic hematopoietic cell transplantation: a randomized trial.
Boeckh M; Nichols WG; Chemaly RF; Papanicolaou GA; Wingard JR; Xie H; Syrjala KL; Flowers ME; Stevens-Ayers T; Jerome KR; Leisenring W
Ann Intern Med; 2015 Jan; 162(1):1-10. PubMed ID: 25560711
[TBL] [Abstract][Full Text] [Related]
36. Infantile nephrotic syndrome secondary to cytomegalovirus infection in a 7-month-old girl: resolution with ganciclovir.
Kaur J; Deepthi B; Dhull RS; Faruq MD; Saha A
Paediatr Int Child Health; 2021 May; 41(2):162-165. PubMed ID: 32990185
[TBL] [Abstract][Full Text] [Related]
37. [Primary focal segmental glomerular sclerosis in children: epidemiology and prognosis].
Tizki S; Lasry F; Khalifa HH; Itri M
Nephrol Ther; 2013 Nov; 9(6):433-7. PubMed ID: 23816889
[TBL] [Abstract][Full Text] [Related]
38. Ganciclovir-Resistant Cytomegalovirus Infection in Abdominal Solid Organ Transplant Recipients: Case Series and Review of the Literature.
Rolling KE; Jorgenson MR; Descourouez JL; Mandelbrot DA; Redfield RR; Smith JA
Pharmacotherapy; 2017 Oct; 37(10):1258-1271. PubMed ID: 28699311
[TBL] [Abstract][Full Text] [Related]
39. Efficacy of valganciclovir in the treatment of cytomegalovirus disease in kidney and pancreas transplant recipients.
Luan FL; Chopra P; Park J; Norman S; Cibrik D; Ojo A
Transplant Proc; 2006 Dec; 38(10):3673-5. PubMed ID: 17175363
[TBL] [Abstract][Full Text] [Related]
40. Successful treatment with foscarnet for ganciclovir-resistant cytomegalovirus infection in a kidney transplant recipient: A case report.
Iwami D; Ogawa Y; Fujita H; Morita K; Sasaki H; Oishi Y; Higuchi H; Hatanaka K; Shinohara N
Nephrology (Carlton); 2016 Jul; 21 Suppl 1():63-6. PubMed ID: 26970406
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
